File:Fmicb-11-01063-g005.jpg

From Wikimedia Commons, the free media repository
Jump to navigation Jump to search

Original file(2,056 × 1,419 pixels, file size: 381 KB, MIME type: image/jpeg)

Captions

Captions

herpes simplex virus

Summary[edit]

Description
English: FIGURE 5. The structures of HSV gH and gB protein in the native and fusion-intermediate states, which serve as sources of protein- and peptide-based HSV inactivators. (A) Schematic representation of HSV-1 gH and gB composition. gH is composed of the ectodomain (H1, H2, and H3 domains, colored mazarine blue, green, and yellow, respectively), transmembrane domain (TM) and cytoplasmic tail (CP). gB is composed of domains I–V, transmembrane region (TM) and cytoplasmic domain (CP). (B) The HSV entry process orchestrated by a set of glycoproteins, including receptor-binding gD, fusion-regulating gH/gL and the fusogen gB. gD binding to either receptor, such as HVEM and nectin-1, causes its conformational change to expose the profusion domain. gB may also bind to specific cell receptors, such as (PILR)α and NMHC-II. Meanwhile, gH/gL may be facilitated by the activated form of gD to convert into a form able to interact with gB, triggering the transformation of the prefusion form of gB into a fusogenic state. Next, Akt (protein kinase B) may be triggered to translocate to the outer leaflet microdomains of the plasma membrane to interact with gB, which further induces Akt phosphorylation and intracellular calcium release. Subsequently gB inserts the fusion loop into the target cell membrane to form the extended, trimeric intermediate, which allows fusion of the two membranes. The pre-fusion conformation of gH/gL and gB are highlighted in a green box, which is shown in more detail in (C). (C) Side view of the pre-fusion conformation of the native gH/gL complex (modified from PDB ID: 3M1C) and gB (modified from PDB ID: 5FZ2). Names and sequences of inactivators are listed in the three boxes, and the arrows depict their positions on gH/gL and gB. Target sites of these inactivators have not been defined clearly, thus not shown here.
Date
Source https://www.frontiersin.org/articles/10.3389/fmicb.2020.01063/full#:~:text=Most%20antiviral%20drugs%20act%20as%20passive%20defenders%20to,as%20well%20as%20virus%20inactivators%20%28including%20attachment%20inhibitors%29.
Author Xiaojie Su, Qian Wang, Yumei Wen, Shibo Jiang

Licensing[edit]

w:en:Creative Commons
attribution
This file is licensed under the Creative Commons Attribution 4.0 International license.
You are free:
  • to share – to copy, distribute and transmit the work
  • to remix – to adapt the work
Under the following conditions:
  • attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

File history

Click on a date/time to view the file as it appeared at that time.

Date/TimeThumbnailDimensionsUserComment
current00:52, 18 January 2024Thumbnail for version as of 00:52, 18 January 20242,056 × 1,419 (381 KB)Ozzie10aaaa (talk | contribs)Uploaded a work by Xiaojie Su, Qian Wang, Yumei Wen, Shibo Jiang from https://www.frontiersin.org/articles/10.3389/fmicb.2020.01063/full#:~:text=Most%20antiviral%20drugs%20act%20as%20passive%20defenders%20to,as%20well%20as%20virus%20inactivators%20%28including%20attachment%20inhibitors%29. with UploadWizard

There are no pages that use this file.

Metadata